Examination of Cognitive Function in Patients Treated With Subutex

This study has been completed.
Sponsor:
Collaborator:
Ebetim Clinic
Information provided by:
BeerYaakov Mental Health Center
ClinicalTrials.gov Identifier:
NCT00687089
First received: May 27, 2008
Last updated: January 25, 2009
Last verified: January 2009

May 27, 2008
January 25, 2009
June 2008
January 2009   (final data collection date for primary outcome measure)
ASI quationarry, neurocognitive computerized tests, MMSE test, Sexual function questionnaire and satisfaction questionnaire [ Time Frame: In 2 visits during the study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00687089 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Examination of Cognitive Function in Patients Treated With Subutex
Examination of Cognitive Function, Weight, Sexual Function in Patients Receiving Treatment With Subutex at 3 Months Without Using Opiates

People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs.

The popular treatment's goal is to "clean" the people from any drug. In a medical and pharmacological point of view there is no sense in this approach for all people. This point of view believes that Buprenorphine (Subutex) is a correct pharmacological treatment.

The hypothesis of this research is that people using Buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports)

People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs.

The popular treatment's goal is to "clean" the people from any drug. In a medical and pharmacological point of view there is no sense in this approach for all people. This point of view believes that Buprenorphine (Subutex) is a correct pharmacological treatment.

The hypothesis of this research is that people using Buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports) We examine people who stopped opiates and began Buprenorphine. Every participant in the study will have two visits: the first one before receiving Buprenorphine and the second one after 3 months of receiving Buprenorphine.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

People who suffer from addiction problems (opiates) and willing to start Buprenorphine treatment

Opiate Addiction
Other: Sexual, cognitive functional tests and measurement weight
Subutex group
People who used opiates and willing to start with subutex treatment
Intervention: Other: Sexual, cognitive functional tests and measurement weight
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
January 2009
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • People who suffer from addiction problems (opiates)
  • People who willing to to start Buprenorphine treatment
  • People who willing to cooperate with study tests and questionnaires
  • People aged 18 to 70

Exclusion Criteria:

  • People who suffer from any neurocognitive problems
  • People who suffer from mental illnesses
  • People who are having legal guardian
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00687089
Subutex-214CTIL
Yes
Aviva Wolf, "Hebetim" psychiatric and psychologic clinic- private clinic
BeerYaakov Mental Health Center
Ebetim Clinic
Not Provided
BeerYaakov Mental Health Center
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP